How are energy investors positioned?
TUCSON, AZ – Accelerate Diagnostics (NASDAQ:AXDX), Inc. has been notified by the Nasdaq Stock Market of a potential delisting due to its Market Value of Listed Securities falling below the required minimum. The laboratory analytical instruments company, headquartered in Tucson, Arizona, disclosed on Monday that it received a notice from Nasdaq on January 28, 2025, indicating that the company’s market value had been below the $35 million threshold for the last 30 consecutive business days.
The company, which is currently listed on the Nasdaq Capital Market under the trading symbol AXDX, has been given 180 calendar days, until July 28, 2025, to regain compliance with the Nasdaq’s Market Value of Listed Securities (MVLS) requirement. To meet this requirement, the market value of Accelerate Diagnostics’ common stock must close at $35 million or more for at least ten consecutive business days before the compliance deadline.
While the notice does not immediately affect the listing of Accelerate Diagnostics’ common stock, failure to meet the MVLS requirement by the deadline could lead to delisting. The company would then have the opportunity to appeal the decision before a Nasdaq Hearing Panel.
Accelerate Diagnostics is currently assessing potential courses of action to regain compliance with the MVLS requirement. It aims to actively monitor its market value but has stated that there is no guarantee it will achieve compliance within the given timeframe or maintain compliance with other Nasdaq listing standards.
This development is based on a press release statement and follows the company’s previous name changes from Accelr8 Technology Corp and Hydro Seek Inc. Investors are watching closely as the company explores options to address this challenge and maintain its Nasdaq listing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.